Search
Bufexamac
go.drugbank.com/drugs/DB13346ApprovedWithdrawnThe use of bufexamac has been discontinued in Canada and the United States, which may be due to undetermined clinical efficacy and a high prevalence of contact sensitization [A32822]. … It has also been used in suppositories in combination with local anaesthetics indicated for haemorrhoids.
Categories: Topical Products for Joint and Muscular Pain, Antiinflammatory Preparations, Non-Steroids for Topical UseSynonyms: 2-(p-Butoxyphenyl)-acetohydroxamic acid, p-Butoxyphenylacetohydroxamic acidCongenital Thrombotic Thrombocytopenic Purpura
go.drugbank.com/conditions/DBCOND0049682Drugs: Apadamtase alfaSynonyms: Familial TTP/HUSPlasma protein fraction (human)
go.drugbank.com/drugs/DB13968ApprovedInvestigationalThe plasma protein fraction human (PPFh) is defined as a sterile solution of proteins composed mainly of albumin and globulin derived from human plasma. It is already reviewed under the category of biologics by the FDA where the processi...
Mixtures: UMAN SERUMProducts: Octaplas SD Blutgruppe 0 zur Infusion, Octaplas SD Blutgruppe A zur InfusionNiclosamide
go.drugbank.com/drugs/DB06803ApprovedInvestigationalVet approvedNiclosamide is an antihelminthic used for the treatment of tapeworm infections. … Over 1 billion people are infected with intestinal nematodes, and many millions are infected with filarial nematodes, flukes, and tapeworms. They are an even greater problem in domestic animals.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsIvosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigational[L46287] It was fully approved by the EMA in May 2023.[L46596] … [L48781] In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSebelipase alfa
go.drugbank.com/drugs/DB11563ApprovedInvestigational[L39337] Sebelipase alfa is a recombinant form LAL approved for the treatment of LAL deficiency. … This lipid accumulation can lead to end-organ damage in the form of liver dysfunction or malabsorption secondary to intestinal dysfunction.
Methyldopa
go.drugbank.com/drugs/DB00968ApprovedInvestigational[A231784] It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. … Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent.
Categories: Antihypertensive Agents Indicated for Hypertension, Adrenergic alpha-2 Receptor AgonistsOxazepam
go.drugbank.com/drugs/DB00842ApprovedOxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. … [A203516] It is an active metabolite of both [diazepam] and [temazepam][A39486] and undergoes very little biotransformation following absorption, making it unlikely to participate in pharmacokinetic interactions
Dasabuvir
go.drugbank.com/drugs/DB09183ApprovedDasabuvir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). … in combination with [DB09296], [DB09297], and [DB00503] for genotype 1b and with [DB00811] for genotype 1a of Hepatitis C [L852].
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseLovastatin
go.drugbank.com/drugs/DB00227ApprovedInvestigational[A181084] Elevated cholesterol levels, and in particular, elevated low-density lipoprotein (LDL) levels, are an important risk factor for the development of CVD. … as well as the need for surgical revascularization or angioplasty following a heart attack.
Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Cytochrome P-450 SubstratesProducts: Ran-lovastatin